Gilead Sciences, Inc. (NASDAQ:GILD) obtains marketing authorization for Yeytuo (lenacapavir) from the European Commission (EC), a twice-yearly injectable HIV-1 capsid inhibitor for PrEP. It is the first approved option in the EU, Iceland, Norway, and Liechtenstein for adults and adolescents at risk of sexually acquired HIV-1.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company specializing in medicines for cancer, HIV, viral hepatitis, and COVID-19. Operating in over 35 countries, its portfolio includes drugs like AmBisome, Atripla, and Biktarvy. While GILD shows investment potential, consider AI stocks for greater upside and lower risk.

Consider Gilead Sciences (GILD) for investment, but explore AI stocks for potential growth. GILD focuses on medicines for serious diseases and operates globally. For undervalued AI stock options, download a free report on the best short-term AI stock. Check out Insider Monkey for more insights on potential investments.

Read more at Yahoo Finance: Gilead Sciences (GILD) Announces Marketing Authorization for Yeytuo from the European Commission